The AutoMicrobic system (Vitek Systems, Inc., Hazelwood, Mo.) is a fully automated, computerized instrument. One of the most thoroughly studied aspects of the system is its ability to identify and quantify the nine most common urinary tract pathogens. The major advantages of the AutoMicrobic system are that the results of urine cultures are available in a fraction of the time required by conventional methods and that samples can be processed with fewer man-hours. Although the specificity, sensitivity, and reliability of the system have been amply described in the literature, only one study combines these aspects with a cost analysis (D. P. Nicholson and J. A. Koepke, J. Clin. Microbiol. 10:823-833, 1979). Because one of the major considerations that microbiology laboratory directors must face is the cost-effectiveness of instruments, we studied the relative cost of the system as compared with that of conventional methods. Our findings indicated that the instrument provided valuable savings in technologist and turnaround time. These advantages were most easily realized in processing positive urine specimens. For negative urine specimens, the savings in technologist time were cancelled by the cost of the consumable supplies, which greatly exceeded the cost of supplies for conventional methods. This disadvantage might be ameliorated by efficient and effective screening methods to exclude those urine specimens that are most probably negative.
time. These advantages were most easily realized in processing positive urine specimens. For negative urine specimens, the savings in technologist time were cancelled by the cost of the consumable supplies, which greatly exceeded the cost of supplies for conventional methods. This disadvantage might be ameliorated by efficient and effective screening methods to exclude those urine specimens that are most probably negative.
The AutoMicrobic system (AMS; Vitek Systems, Inc., Hazelwood, Mo.) is an automated and computerized instrument with multiple applications (1, (3) (4) (5) (6) (7) . The AMS has the clinical advantage of providing specific, quantitative results of urine cultures in a fraction of the time required for conventional methods. At least three evaluations of the performance of the system on simulated (6) and clinically collected (4, 5) urine specimens indicate a high degree of correlation with conventional methods. Smith et al. (6) , in a collaborative group study, found that the sensitivity of the AMS in identifying common urinary tract pathogens was 92.8%. In the same study, the specificity averaged 99.4%, and the reliability of a positive result averaged 92 pose of Nicholson and Koepke's study was evaluative, the relative cost and time analysis of the AMS was brief. Therefore, to provide practical guidelines for laboratory directors, we designed a study which would provide in-depth comparative data on the potential cost, time, and labor savings of the AMS versus conventional methods for urine cultures.
To determine all aspects of cost, we limited our study to performance characteristics which directly affected the cost and benefit analysis of the AMS, particularly the definitions of truepositive, true-negative, false-positive, false-negative, and relative incidences. (1) .
MATERIALS AND METHODS
Evaluation of the AMS. The AMS identifications were compared with those of conventional methods and the API system (Analytab Products, Plainview, N.Y.). Whenever a discrepancy was observed in quantitation or identification, it was investigated as thoroughly as possible. For false-positive samples, the cards were inspected visually to exclude such obvious problems as bubbles, and then the contents of the positive well of the urine identification card were streaked onto a blood agar-MacConkey agar biplate in an attempt to resolve the discrepancy.
Cost-effectiveness and time factor analysis. The cost of expendable items and labor for the AMS was compared with that for conventional methods by calculating the cost of reagents used in each method and the actual time spent at the bench in processing the specimens. We determined the average time spent by two or three technologists or technicians (as appropriate) performing each task for urine identification and quantitation. A real time, effort, and materials log was kept for all specimens during the 6-week trial period. These data were expressed as labor and materials required per month based on an average work load of 900 specimens per month.
RESULTS
The overall performance of the AMS is shown in Table 1 . A true-positive response was defined as total agreement between the AMS and conventional methods both in identification and enumeration; a true-negative response was the converse. A sample was also considered truenegative if one system yielded a negative result and the other yielded low counts of possible contaminants (<30,000 colony-forming units per ml). A false-negative response occurred when the AMS yielded a negative result in spite of the presence of -:5 x 104 colony-forming units of an organism per ml growing on the biplate. An enumeration error was defined as a significant discrepancy between the AMS and conventional method counts, given the enumerative characteristics of the automated system. A sample was deemed misidentified if there was a discrepancy between the AMS identification and the conven- tional method identification.
The combined AMS error rate (false-negatives, enumeration errors, and misidentifications) was 3.5% during our trial (Table 1) . This rate agrees with rates found in other studies.
To carry out a comprehensive materials and labor analysis, we further divided the results for the 1,478 urine cultures into three categories (Tables 2 and 3 ). Eighty-four percent of the samples required no further analysis with either analytical method. These included true-negatives, false-positives, heavily contaminated urine specimens, and misidentified specimens of low counts (category A). Ten percent of the samples did not need further analysis with the AMS, but did with conventional methods. These included Escherichia coli, enterococci, Pseudomonas aeruginosa, Citrobacter freundii, or any combination of the above (category B). Six percent of the specimens needed further analysis with either method. These included yeasts, Staphylococcus aureus, false-negatives, and unidentified and misidentified organisms with counts of >5 X 104 colony-forming units per ml. The group that needed further identification included Proteus spp. and the Klebsiella/Enterobacter/Serratia group (category C). Some laboratories might not want to process some organisms of the latter group further.
The total cost of processing 900 urine specimens per month is shown in Table 3 . The cost of processing a negative urine specimen and the cost of processing a positive urine specimen for an organism fully identifiable by the AMS are shown in Tables 4 and 5 . The AMS took 70% of the time that conventional methods took to identify a negative urine specimen, but the cost for the AMS identification was more than two times that for conventional methods. The AMS took 30% of the time that conventional methods took to identify a positive urine specimen and cost 30% less than conventional methods.
DISCUSSION
The AMS is a fully automated instrument with multiple applications (1, 3-7) . These include, among others, detection, enumeration, and identification of bacteria in urine (4-7), identification of gram-negative organisms (3), and determination of general susceptibilities of gram-negative organisms.
We analyzed and compared the cost of the AMS with the operational cost of conventional methods. According to the data shown in Table  3 , the bulk of the expenditure for the AMS is due to the cost of expendables, which are 2.5 times more costly than those for conventional methods. On the other hand, the AMS process- (43) Uni-Yeast-Tek (6) Uni-Yeast-Tek (6) Coagulase test (6) Coagulase test (6) CAMP test (6) CAMP test (6) Salt/PSE (4) Salt/PSE (4) a The categories and percentages were derived from the original 6-week trial of 1,478 samples and were applied to a monthly workload of 900 urine cultures. b The numbers in parentheses represent the number of specimens that required the indicated materials for correct identification. Salt, Growth in 6.5% NaCl; PSE, Pfizer's media selective for enterococcus. ing takes 30% less time than processing by conventional methods. The bulk of the time spent in processing urine specimens with the AMS is for setup, which can be performed by a laboratory technician. The man-hours spent for AMS processing cost 20% less than they do for processing by conventional methods. In addition to these savings with the AMS in man-hours, which were included in the cost anal- The AMS is cost-effective in processing positive urine specimens (Table 5) . However, the cost of processing a negative urine specimen is more than twice that incurred with conventional methods ( The A'MIS is cost-effective for identifying gram-negative organisms; patient care benefits resulting from this and other applications are obvious, the mnost notable being the shorter turnaround time and the freeing of the technologist. Another benefit of the AMS is that the interpretation of biochemical tests is done automatically, eliminating the possibility of subjective error.
The AMS has two drawbacks. The first is that 3.5% of the specimens examined will be misidentified, missed, or not enumerated accurately; the second is that results can occasionally be lost because of electrical or mechanical failure. These factors can be ameliorated by processing a backup blood plate simultaneously with the AMS urine identification cards whenever the latter are being used. The results from this backup plate can be checked the next morning and compared with those of the AMS. The report can be signed out if there are no major discrepancies. The susceptibility profiles can also be used as a check for the accuracy of the AMS identification.
In summary, we feel that the AMS provides valuable savings in technologist and turnaround time. It is cost-effective for identifying the nine most common urinary tract pathogens. For negative urine specimens, when the cost of expendables for the AMS exceeds that of expendables for conventional methods, the cost savings are eliminated.
The most cost-effective beneficial application of the AMS system occurs when the urine specimens are screened and only the positive specimens are processed with the AMS. In such cases, we have shown that the AMS is significantly less expensive and faster. Both are important considerations for optimum patient care.
